Medical/Pharmaceuticals
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...
2023-11-14 06:40
2810
OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002
SEOUL, South Korea, Nov. 13, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed uncanny clinical findings from a multi-center Phase 2a trial with Nav1.7 selective OLP-1002 in osteoarthritis (OA) patients with moderate to severe pain inAustralia with Novotech...
2023-11-13 22:00
2309
Datasea Reports First Quarter Fiscal Year 2024 Financial Results and Operations Update
BEIJING, Nov. 13, 2023 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a global technology company that develops and provides products utilizing intelligent acoustics including ultrasound, infrasound and directional sound, and provides 5G messaging, today announced its f...
2023-11-13 21:30
3238
AnchorDx, DiaCarta Partner Developing Novel Cancer Screening Tests
GUANGZHOU, China, Nov. 13, 2023 /PRNewswire/ -- AnchorDx, a leading diagnostics company developing cancer early detection tests, announced today that it has entered into a long-term collaboration with DiaCarta, a precision molecular diagnostics company and developer of novel oncology and infectio...
2023-11-13 21:00
2105
PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
* PYC has developed a new drug candidate for the >5 million people worldwide [1] with Polycystic Kidney Disease (PKD) * This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD[2] * PKD is a life-changing diseas...
2023-11-13 21:00
2470
BizLink once again proves its ability to innovate in healthcare robotics
At the MEDICA show in Duesseldorf, BizLink presents its new PULSAR platform, an ultrasafe and precise range of robotic arms for medical para-medical applications. CHARTRES, France, Nov. 13, 2023 /PRNewswire/ -- BizLink, a leading global interconnect solutions provider, announced the introduction...
2023-11-13 17:53
3259
Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates
CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, today announced that it has entered into a strategic collaboration with GeneQuantum Healthcare to advance the early discovery of next-gener...
2023-11-13 16:04
1970
Fapon Inaugurates State-of-the-Art R&D Center in Lexington, MA
LEXINGTON, Mass., Nov. 11, 2023 /PRNewswire/ -- Fapon, a global leading life sciences organization, is thrilled to announce the grand opening of its US-based Research and Development (R&D) Center, strategically located in Lexington, Massachusetts. This Center represents Fapon's unwavering commitme...
2023-11-11 20:36
4187
SeekIn Presents Retrospective and Prospective Validation Studies of SeekInCare Multi-omics Multi-cancer Early Detection test at the 20th ICGC Workshop and 7th ARGO Meeting in New York
One Retrospective Cohort, One Prospective Cohort, in Total of ~2,400 Cancer Patients and Non-cancer Individuals Demonstrate the Performance of SeekInCare Test to Detect Multiple Cancer Types and Predict Tissue of Origin of Cancers The Achievement of 65.5% Sensitivity at 97.9% Specificity in the ...
2023-11-10 21:00
2860
Lecheng, MSD vow to deepen medical cooperation
BEIJING, Nov. 10, 2023 /PRNewswire/ -- A news report from chinadaily.com.cn:
2023-11-10 18:03
3577
FEBICO actively seeking business partners in United States, introduces "High- Spermidine" chlorella health supplements to satisfy U.S. market
TAIPEI, Nov. 10, 2023 /PRNewswire/ -- FEBICO
2023-11-10 17:08
1757
TCT 2023: The Efficacy and Safety of the SMART Trial Presented by World Renowned Expert
SAN FRANCISCO, Nov. 10, 2023 /PRNewswire/ -- On October 26, 2023, SyMap Medical invited ProfessorFelix Mahfoud, Vice-Chair of the Working Group Interventional Hypertension Treatment of the European Society of Hypertension (ESH) and a distinguished authority in the renal denervation (RDN) field, t...
2023-11-10 16:46
2253
GC Genome Enters License Agreement with MP Group
- Collaboration includes the transfer of GC Genome's essential wet lab know-how for SNP genotyping service. YONGIN, South Korea, Nov. 10, 2023 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it has entered into a collaboration and exclusive license agre...
2023-11-10 13:00
2699
MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results
SHENZHEN, China, Nov. 9, 2023 /PRNewswire/ -- On November 9, 2023, ImmVira announced the successful completion of Phase I clinical study conducted on late-stage patients with various tumor types for our intravenous oncolytic product, MVR-T3011 IV, inthe United States. This milestone was marked by...
2023-11-10 08:00
2748
PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data
* Safety Review Committee evaluated dose level 1 safety data of PMC-403 and approved advancing to the higher dose treatment. * The starting dose (0.7mg) of PMC-403 showed potential in improving eyesight for neovascular age-related macular degeneration patients with suboptimal response to cur...
2023-11-09 21:00
2503
Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases
Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to$1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments. AstraZeneca will receive an exclusive license to develop and commercialize ECC5004 in al...
2023-11-09 15:05
2636
WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan
SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, recei...
2023-11-09 08:00
3249
Holmusk Appoints Eze Abosi as Chief Growth Officer
New CGO joins Holmusk during a period of strong and sustainable growth for both
the life science and payer/provider businesses.
NEW YORK, Nov. 8, 2023 /PRNewswire/ -- Holmusk
2023-11-09 08:00
3225
Porton Advanced Announces a Strategic Partnership with BioMap, with AI Models Facilitating AAV Gene Therapy Development
SUZHOU, China, Nov. 8, 2023 /PRNewswire/ -- On November 8, 2023, Porton Advanced announced the establishment of a strategic partnership with BioMap. BioMap will leverage Porton Advanced's unique Adeno-Associated Virus (AAV) vector technology platform and research data to develop AAV assembly effi...
2023-11-08 22:31
3334
WuXi Biologics Receives AAA MSCI ESG Rating
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings, the highest rating for compan...
2023-11-08 08:30
2604
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 294 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
9295
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7719
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
6962
CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
2026-09-15 19:07
6289
